title: Omega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemia.
abstract: The 2013 American College of Cardiology/American Heart Association guidelines on cholesterol management placed greater emphasis on statin therapy given the well-established benefits in primary and secondary prevention of cardiovascular disease. Residual risk may remain after statin initiation, in part because of triglyceride-rich lipoprotein cholesterol. Several large trials have failed to show benefit with non-statin cholesterol-lowering medications in the reduction of cardiovascular events. Yet, subgroup analyses showed a benefit in those with hypertriglyceridemia and lower high-density lipoprotein cholesterol level, a high-risk pattern of dyslipidemia. This review discusses the benefits of omega-3 carboxylic acids, a recently approved formulation of omega-3 fatty acid with enhanced bioavailability, in the treatment of dyslipidemia both as monotherapy and combination therapy with a statin.
authors.affiliation: Department of Medicine, Section of Cardiology.
authors.forename: Lane B
authors.initials: LB
authors.lastname: Benes
authors.affiliation: Department of Medicine, University of Chicago, Chicago, IL, USA.
authors.forename: Nikhil S
authors.initials: NS
authors.lastname: Bassi
authors.affiliation: Department of Medicine, Section of Cardiology.
authors.forename: Michael H
authors.initials: MH
authors.lastname: Davidson
mesh_terms: D001682:Biological Availability; D015415:Biomarkers / Q000097:blood; D002264:Carboxylic Acids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000175:diagnosis / Q000209:etiology / Q000517:prevention & control*; D004339:Drug Compounding; D004359:Drug Therapy, Combination; D015525:Fatty Acids, Omega-3 / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D015228:Hypertriglyceridemia / Q000097:blood / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy*; D008055:Lipids / Q000097:blood*; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D002264:Carboxylic Acids; D015525:Fatty Acids, Omega-3; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008055:Lipids
keywords: hypertriglyceridemia; non-HDL-C; omega-3 carboxylic acids; residual risk; statin